Roivant Sciences Ltd.

ROIV · Nasdaq · United Kingdom

Share price · ROIV

$38.73+1.36 (+3.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.7M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ROIV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Sep 2026+18.8%
  2. 28 Aug 2026-7.6%
  3. 21 May 2026-4.7%
  4. 20 May 2026+14.9%
  5. 9 Feb 2026+7.2%
  6. 6 Feb 2026+22.1%
  7. 13 Jan 2026+5.8%
  8. 16 Dec 2025+4.7%
  9. 11 Dec 2025+5.4%

Share of unusual movement by asset

For each asset, the share of ROIV's own-move activity since 10 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
brepocitinib (Lisraya)
events and moves
6shown from 8 days
Mosliciguat
events and moves
3shown from 8 days
Imeroprubart
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—52%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—35%

Assets

(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
12Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
brepocitinib(Lisraya)
Approved
TYK2/JAK1Small molecule
PsoriasisDermatomyositisNon-Infectious UveitisCutaneous SarcoidosisLichen PlanopilarisIdiopathic Inflammatory Myopathies
Phase 3
FcRnMonoclonal antibody
Rheumatoid ArthritisMyasthenia GravisGraves' DiseaseChronic Inflammatory Demyelinating PolyneuropathySjögren's Disease
Phase 3
Soluble guanylate cyclaseSmall molecule
Pulmonary Hypertension Associated with Interstitial Lung Disease

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MosliciguatPhase 2Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2026-12 · NCT07333183 · CT.gov ↗
What to watch
2027 (3)
May 2027 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2027-05 · NCT07018323 · CT.gov ↗
What to watch
September 2027 (1)
ImeroprubartPhase 2Rheumatoid Arthritis
Est. primary completion 2027-09 · NCT06754462 · CT.gov ↗
What to watch
December 2027 (1)
ImeroprubartPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-12 · NCT07039916 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2028-06 · NCT06727604 · CT.gov ↗
What to watch
July 2028 (1)
ImeroprubartPhase 2Primary Sjögren's Syndrome
Est. primary completion 2028-07 · NCT06979531 · CT.gov ↗
What to watch
August 2028 (1)
ImeroprubartPhase 2Chronic Inflammatory Demyelinating Polyneuropathy
Est. primary completion 2028-08 · NCT07032662 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
MosliciguatPhase 3Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2029-01-28 · NCT07816185 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2030-03 · NCT07286006 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026Topline resultImeroprubartRandomized withdrawal period (Period 2) in difficult-to-treat RA met its primary endpoint

Recent

21 October 2026Topline resultbrepocitinibPhase 3 CLARITY-1 and CLARITY-2 of brepocitinib in non-infectious uveitis met their primary endpoint (time to treatment failure)
Roivant Sciences and Priovant Therapeutics · Source ↗
23 September 2026Topline resultIMVT-1402IMVT-1402 CLE proof-of-concept study misses primary endpoint; CLE development stopped
Immunovant, Inc. · Source ↗
8 September 2026Topline resultMosliciguatPhase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint
Roivant Sciences Ltd. · Source ↗
27 August 2026ApprovalbrepocitinibFDA approves LISRAYA (brepocitinib) for adults with dermatomyositis
US, FDA · Source ↗
27 August 2026ApprovalbrepocitinibFDA Boxed Warning on Lisraya (NDA220106)
US, FDA · FDA · Source ↗
10 September 2024Topline resultMosliciguatPhase 1b ATMOS proof-of-concept results for inhaled mosliciguat

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$35M$146M$1.6B+ $2.6B short-term inv.$192M$594M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.4M$202M$1.3B+ $2.6B short-term inv.$190M-$271M operating cash flowreport ↗
2025-Q4$2.0M$165M$1.5B+ $3.1B short-term inv.$266M-$196M operating cash flowreport ↗
2025-Q3$1.6M$165M$1.2B+ $3.1B short-term inv.$114M-$186M operating cash flowreport ↗
2025-Q2$2.2M$153M$1.2B+ $3.3B short-term inv.$223M-$204M operating cash flowreport ↗
2024-Q4$9.0M$142M$2.0B+ $3.2B short-term inv.—-$207M operating cash flowreport ↗
2024-Q3$4.5M$143M$2.0B+ $3.4B short-term inv.$230M-$267M operating cash flowreport ↗
2024-Q2$55M$133M$5.7B—-$193M operating cash flowreport ↗
2023-Q4$37M$124M$6.7B—-$210M operating cash flowreport ↗
2023-Q3$37M$132M$1.4B$304M-$196M operating cash flowreport ↗
2023-Q2$22M$125M$1.4B$292M-$250M operating cash flowreport ↗
2022-Q4$17M$126M$1.5B$352M-$223M operating cash flowreport ↗
2022-Q3$13M$132M$1.6B$292M-$190M operating cash flowreport ↗
2022-Q2$4.3M$136M$2.0B$332M-$252M operating cash flowreport ↗
2021-Q4$24M$153M$2.2B$285M-$268M operating cash flowreport ↗
2021-Q3$14M$254M$2.5B$208M-$121M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$8.3M$682M$1.4B+ $2.9B short-term inv.$75M-$750M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$29M$550M$2.7B+ $2.2B short-term inv.$43M-$839M operating cash flowreport ↗
2024-FY$125M$502M$6.6B+ $0 short-term inv.—-$765M operating cash flowreport ↗
2023-FY$61M$525M$1.7B$252M-$843M operating cash flowreport ↗
2022-FY$55M$483M$2.1B$211M-$678M operating cash flowreport ↗
2021-FY$24M$237M$2.1B$202M-$552M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 129 sales ($959.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17QVT Financial LP · Director by DeputizationOther (see filing)2,635,169——Form 4
2026-11-17Gold Daniel Allen · directorOther (see filing)2,635,169——Form 4
2026-11-17MANCHESTER KEITH S · directorOther (see filing)2,635,169——Form 4
2026-11-17QVT Financial LP · Director by DeputizationOther (see filing)15,969——Form 4
2026-11-17Gold Daniel Allen · directorOther (see filing)15,969——Form 4
2026-11-17MANCHESTER KEITH S · directorOther (see filing)15,969——Form 4
2026-11-17QVT Financial LP · Director by DeputizationOther (see filing)385,620——Form 4
2026-11-17Gold Daniel Allen · directorOther (see filing)385,620——Form 4